AstraZeneca Reports Seven-Year SOLO-1 Data for Lynparza in BRCA-Mutated Ovarian Cancer

AstraZeneca today presented seven-year overall survival data from the Phase 3 SOLO-1 trial evaluating Lynparza (olaparib) as maintenance therapy in patients with newly diagnosed advanced BRCA-mutated ovarian cancer. The data showed a significant improvement in overall survival with Lynparza, with a median overall survival of 75.2 months compared to 57.3 months in the placebo arm.